Follow
Sophie Whyte
Title
Cited by
Cited by
Year
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
KL Cooper, J Madan, S Whyte, MD Stevenson, RL Akehurst
BMC cancer 11, 1-11, 2011
3192011
British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection …
MD Rutter, J East, CJ Rees, N Cripps, J Docherty, S Dolwani, PV Kaye, ...
Gut 69 (2), 201-223, 2020
2052020
Distributional cost‐effectiveness analysis of health care programmes–a methodological case study of the UK bowel cancer screening programme
M Asaria, S Griffin, R Cookson, S Whyte, P Tappenden
Health economics 24 (6), 742-754, 2015
1352015
Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible …
L Sharp, L Tilson, S Whyte, A O'ceilleachair, C Walsh, C Usher, ...
British journal of cancer 106 (5), 805-816, 2012
1052012
Bayesian calibration of a natural history model with application to a population model for colorectal cancer
S Whyte, C Walsh, J Chilcott
Medical decision making 31 (4), 625-641, 2011
822011
Cost-effectiveness of granulocyte colony–stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom
S Whyte, KL Cooper, MD Stevenson, J Madan, R Akehurst
Value in Health 14 (4), 465-474, 2011
722011
Cost of care for colorectal cancer in Ireland: a health care payer perspective
L Tilson, L Sharp, C Usher, C Walsh, W S, A O¢Ceilleachair, C Stuart, ...
The European journal of health economics 13, 511-524, 2012
682012
Eliciting societal preferences for weighting QALYs for burden of illness and end of life
D Rowen, J Brazier, C Mukuria, A Keetharuth, A Risa Hole, A Tsuchiya, ...
Medical Decision Making 36 (2), 210-222, 2016
562016
Reappraisal of the options for colorectal cancer screening in England
S Whyte, J Chilcott, S Halloran
Colorectal Disease 14 (9), e547-e561, 2012
532012
Consistency between direct and indirect trial evidence: is direct evidence always more reliable?
J Madan, MD Stevenson, KL Cooper, AE Ades, S Whyte, R Akehurst
Value in Health 14 (6), 953-960, 2011
512011
Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal
S Whyte, A Pandor, M Stevenson
Pharmacoeconomics 30, 1119-1132, 2012
462012
Estimating the cost-effectiveness of implementation: is sufficient evidence available?
S Whyte, S Dixon, R Faria, S Walker, S Palmer, M Sculpher, S Radford
Value in Health 19 (2), 138-144, 2016
362016
Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
S Whyte, A Pandor, M Stevenson, A Rees
Health Technology Assessment 14 (2), 47-53, 2010
312010
Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation
B Kearns, J Chilcott, S Whyte, L Preston, S Sadler
BMC medicine 14, 1-10, 2016
302016
Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland
L Sharp, L Tilson, S Whyte, AO Ceilleachair, C Walsh, C Usher, ...
BMC health services research 13, 1-12, 2013
292013
The costs and benefits of risk stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis
C Thomas, O Mandrik, CL Saunders, D Thompson, S Whyte, S Griffin, ...
Cancer Prevention Research 14 (8), 811-822, 2021
272021
Virtual chromoendoscopy for the real-time assessment of colorectal polyps in vivo: a systematic review and economic evaluation
J Picot, M Rose, K Cooper, K Pickett, J Lord, P Harris, S Whyte, D Bohning, ...
Health Technology Assessment 21 (79), 2017
272017
Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme
B Kearns, S Whyte, J Chilcott, J Patnick
British journal of cancer 111 (9), 1734-1741, 2014
222014
How to invest in getting cost-effective technologies into practice? A framework for value of implementation analysis applied to novel oral anticoagulants
R Faria, S Walker, S Whyte, S Dixon, S Palmer, M Sculpher
Medical Decision Making 37 (2), 148-161, 2017
212017
Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing: a report of the main survey
J Brazier, D Rowen, C Mukuria, S Whyte, A Keetharuth, A RiseHole, ...
Policy Research Unit in Economic Evaluation of Health and Care Interventions, 2013
212013
The system can't perform the operation now. Try again later.
Articles 1–20